全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Born in 1979, Yao Sheng has got his Ph. D. in Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2008. He made his postdoctoral stay in the Institute of Organic Chemistry, University of Wuppertal. Yao is now a principal investigator of Shanghai Institute of Materia Medica, CAS & Zhongshan Institute of Drug Discovery. His research mainly focuses on the discovery of natural products with novel structures and potential bioactivities, the chemical essence of traditional usages of Traditional Chinese Medicine and folk herbs, as well as to find potential pharmaceutical lead compounds for drug discovery from Chinese herbal medicines or plants. To date, he has published over 70 academic SCI papers with over 900 citations.  

Education

2005.09-2008.06 Ph.D. Medicinal Chemistry, Shanghai Institute of Materia Medica, CAS, China,

2002.09-2005.07 M.S. Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.

1998.09-2002.07 B.S. Pharmacy, Wuhan University, Wuhan, China.

Work Experience 

2022.07-Current, Principal investigator & Professor in Natural Product Research Center, Shanghai Institute of Materia Medica, CAS, Shanghai, China & TCM Modernization Research Center, Zhongshan Institute of Drug Discovery, Zhongshan, China.

2017.10-2022.06, Professor in Natural Product Research Center, Shanghai Institute of Materia Medica, CAS, Shanghai, China.

2012.10-2017.10, Associate professor in Natural Product Research Center, Shanghai Institute of Materia Medica, CAS, Shanghai, China.

2008.11-2011.01, Postdoctoral Research Fellow in the Institute of Organic Chemistry, University of Wuppertal, Wuppertal, Germany.

2008.07-2012.09, Assistant professor in Natural Product Research Center, Shanghai Institute of Materia Medica, CAS, Shanghai, China. 

1. Discovery of natural products with novel structures and potential bioactivities from Chinese herbal medicines or plants,

2. Study on the chemical essence of traditional usages of Traditional Chinese Medicine and folk herbs,

3. Drug discovery based on natural potential pharmaceutical lead compounds from Chinese herbal medicines or plants.

1. It is the first time to discover the chemical essence and action mode of Shuanghuanglian oral liquid against SARS-Cov-2. Additionally, the first non-covalent inhibitor of SARS-Cov-2 3CLpro from natural sources was discovered and showed potential anti-virus in vitro (APS, 2020, cover paper), which provide a scientific reference and excellent example for the interpretation of the scientific essence of Heat-Clearing and Detoxifying for TCM against COVID-19. Till now, the citations of this paper have exceeded 150 times since it was published in July 2020.

2. Myricetin and dihydromyricetin, were found to be as two naturally covalent 3CLpro inhibitors with high potency against SARS-Cov-2. Additionally, it is the first time to identify the pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Structure-based optimization of myricetin led to the discovery of derivatives with good antiviral activity and the potential of oral administration. These results provide detailed mechanistic insights into the covalent mode of action by pyrogallol-containing natural products and a template for design of nonpeptidomimetic covalent inhibitors against 3CLpros in the fighting against COVID-19 (Nat Commun., 2021).

1.  Hu BT^#, Li H^#, Tang CP, Ke CQ, Geng MY, Yao S*, Xie ZQ*, and Ye Y*. Withaphysalins from Medicinal and Edible Physalis minima and Their Anti-inflammatory Activities. J. Agric. Food Chem. 2022, 70, 18, 5595–5609.

2.  Wang L^#, Wu Y^#, Yao S^#, Ge H^#, Zhu Y, Chen K, Chen WZ, Zhang Y, Zhu W, Wang HY, Guo Y, Ma PX, Ren PX, Zhang XL, Li HQ, Ali MA, Xu WQ, Jiang HL, Zhang LK*, Zhu LL*, Ye Y*, Shang WJ* and Bai F*. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein, Acta Pharmacologica Sinica 2022, 43:788-796 (封面文章).

3.  Wang X^#, Peng X^#, Tang CP, Zhou SZ, Ke CQ, Liu YL, Yao S*, Ai J*, Ye Y*. Anti-inflammatory Eudesmane Sesquiterpenoids from Artemisia hedinii. J Nat Prod, 2021, 84(5):1626-1637.

4.  Su HX^#, Yao S^#, Zhao WF^#, Zhang YM^#, Liu J^#, Shao Q^#, Wang QX, Li MJ, Xie H, Shang WJ, Ke CQ, Feng L, Jiang XR, Shen JS, Xiao GF, Jiang HL, Zhang LK*, Ye Y*, Xu YC*. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun., 2021, 12, 3623.

5.  Su HX^#, Yao S^#, Zhao WF^#, Li MJ^#, Liu J^#, Shang WJ^#, Xie H, Ke CQ, Hu HC, Gao MN, Yu KQ, Liu H, Shen JS, Tang W, Zhang LK, Xiao GF, Ni L, Wang DW, Zuo JP, Jiang HL, Bai F*, Wu Y*, Ye Y*, Xu YC*. In vitro anti-SARS-CoV-2 activities of Shuanghuanglian and its ingredients. Acta Pharmacologica Sinica 2020, 41(9):1167-1177. (封面文章).

7.  Guo W^#, Yao S^#, Sun P, Yang TB, Tang CP, Zheng MY, Ye Y*, and Meng LH*. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening. Acta Pharmacologica Sinica 2020, 41, 423-431.  

8.  Liu M, Yuan J, Hu WJ, Ke CQ, Zhang YF, Ye Y, Zhong DF, Zhao GR*, Yao S* and Liu J*. Pretreatment with broad-spectrum antibiotics alters the pharmacokinetics of major constituents of Shaoyao-Gancao decoction in rats after oral administration. Acta Pharmacologica Sinica 2019, 40, 288-296.

9.  Feng L, Mandi A, Tang CP, Kurtan T, Tang S, Ke CQ, Shen N, Lin G, Yao S*, Ye Y*. A Pair of Enantiomeric Bis-seco-abietane Diterpenoids from Cryptomeria fortune. Journal of Natural Products, 2018, 81, 2667-2672.

10.  Huang XH, Tao LX, Ke CQ, Tang CP, Zhang HY, Ye Y, Lin LG* and Yao S*. Taxodikaloids A and B, Two Dimeric Abietane-Type Diterpenoids from Taxodium ascendens Possessing an Oxazoline Ring Linkage, Org. Lett., 2017, 19 (3), 556–559.